Ultragenyx pharmaceutical inc. (RARE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-424,996

-402,727

-396,748

-371,064

-324,620

-197,611

-191,516

-183,433

-203,596

-302,139

-291,695

-277,375

-261,407

-245,874

-229,807

-204,132

-176,996

-145,618

-107,136

-83,753

-67,551

-59,802

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

80,107

78,568

75,081

72,312

68,014

62,011

58,525

52,591

48,309

44,260

38,462

32,693

24,884

17,396

11,152

7,007

5,394

0

0

0

Amortization of discount on investment securities, net

5,674

6,214

5,740

4,688

3,241

2,641

1,577

258

-2,016

-1,706

-2,063

-2,678

-2,465

-4,842

-6,167

-6,619

-6,500

-5,637

-4,856

-4,437

-4,086

-3,600

0

0

0

Depreciation and amortization

9,272

8,539

9,313

11,523

15,497

19,538

19,109

15,849

10,824

5,825

4,468

4,404

4,041

3,424

2,747

2,157

1,727

1,384

1,116

869

768

684

0

0

0

Revaluation of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,324

0

0

0

Foreign currency remeasurement loss

-573

-688

-381

-30

-1,125

-5,309

-7,266

-3,432

1,597

7,018

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of investment in Arcturus equity securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash collaboration royalty revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of priority review vouchers

-

-

-

-

-

170,300

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

13,705

20,104

14,002

3,491

11,983

7,583

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

655

4,451

7,088

8,738

7,619

5,283

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

21,898

8,216

859

11,006

10,446

14,285

18,027

4,900

3,070

-3,113

554

2,124

2,189

7,147

6,569

8,184

10,211

7,131

6,777

4,485

2,638

4,081

0

0

0

Receivable related to the Daiichi Sankyo license agreement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets

12,818

14,176

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use lease assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued, and other liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

0

0

-188

-

-523

290

-301

1,242

1,134

656

1,282

-179

-91

-339

231

411

0

0

0

Accounts payable

-

-

-

-

-

-

0

0

-847

-

2,539

6,030

2,853

2,502

2,404

-3,934

219

-1,982

-60

5,994

1,556

3,177

0

0

0

Lease liabilities

14,251

15,552

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities and other liabilities

-

-

-

-

-

-

0

0

-4,741

-

8,054

24,282

21,588

32,189

27,493

14,073

14,137

16,670

12,527

7,031

5,331

3,481

0

0

0

Net cash used in operating activities

-344,760

-345,383

-329,197

-309,848

-296,863

-290,566

-316,536

-309,372

-282,116

-253,843

-219,700

-186,452

-177,285

-160,975

-153,739

-155,595

-133,213

-105,977

-77,987

-58,416

-51,672

-44,634

0

0

0

Investing activities:
Purchase of property and equipment

35,869

24,832

14,524

10,523

6,660

4,076

3,783

3,784

2,783

2,793

2,560

4,528

9,196

10,188

11,445

10,422

5,973

4,955

3,485

1,946

2,039

2,149

0

0

0

Purchase of investments

717,319

692,824

620,014

562,201

509,700

509,796

500,046

431,962

403,790

230,487

361,457

426,575

411,887

442,490

458,428

604,945

665,102

624,226

525,351

322,078

198,228

208,972

0

0

0

Proceeds from the sale of investments

36,718

42,718

0

0

0

-

-

-

-

157,934

73,909

107,866

141,477

140,556

120,300

123,390

88,049

89,321

0

0

0

-

-

-

-

Proceeds from maturities of investments

723,838

676,238

607,033

491,909

382,287

302,564

288,863

231,064

268,932

273,632

279,844

335,353

336,785

403,239

416,858

362,308

318,241

249,050

187,883

154,356

121,750

82,972

0

0

0

Proceeds from sale of priority review vouchers

-

-

-

-

-

170,322

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (increase) in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,575

1,845

1,726

1,541

168

1,239

1,358

293

0

0

0

Net cash used in investing activities

-6,971

-13,039

-6,744

-69,853

-63,496

-33,331

-49,501

-35,918

-4,926

55,482

-9,062

13,659

58,722

91,117

64,710

-131,514

-266,511

-292,351

-275,812

-145,642

-62,107

-123,440

0

0

0

Financing activities:
Proceeds from the issuance of common stock in connection with the license agreement, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock in connection with underwritten public offerings, net

-

330,415

330,415

330,415

330,415

270,969

0

0

0

-

-

-

-

-

-

-

-

461,136

460,834

238,221

235,636

188,581

0

0

0

Proceeds from the issuance of common stock in connection with at-the-market offering, net

-

24,828

35,258

51,095

45,553

38,056

91,970

76,133

76,177

131,960

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock from exercise of warrants and equity plan awards, net

6,312

9,829

10,432

18,715

28,083

27,828

31,055

23,201

11,515

9,251

8,372

10,424

8,898

7,834

0

0

0

-

-

-

-

-

-

-

-

Principal repayments of financing leases

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,346

0

0

0

Net cash provided by financing activities

381,304

679,306

376,105

400,225

404,051

336,853

389,050

365,359

353,717

136,267

146,768

208,882

207,331

138,676

64,623

289,827

292,447

467,573

467,098

238,957

236,372

184,971

0

0

0

Effect of exchange rate changes on cash

-590

-165

-357

145

-919

-472

-256

242

760

528

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

28,983

320,719

39,807

20,669

42,773

12,484

22,757

20,311

67,435

-61,566

-81,892

35,663

88,720

68,753

-24,406

2,718

-107,277

69,245

113,299

34,899

122,593

16,897

0

0

0

Supplemental disclosures of non-cash information:
Acquired lease liabilities arising from obtaining right-of-use assets

20,978

21,861

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liability to equity upon conversion to common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,743

0

0

0

Conversion of Series A and Series B preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

129,360

0

0

0